Answers are grounded in this paper and cite their sources.
Patients with chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature/proteasome-associated autoinflammatory syndrome (CANDLE/PRAAS) respond to the janus kinase inhibitor 1/2 inhibition with baricitinib at exposures higher than in rheumatoid arthritis. Baricitinib dose reductions to minimise exposure triggered disease flares which we used to develop 'flare criteria'.
No takes yet. Share an insight, caveat, or question.
Gedik et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: